Pharmaceutical care and home delivery of medication to patients with chronic myeloid leukemia

Pharmaceutical care and home delivery of medication to patients with chronic myeloid leukemia

Objectives: To describe the implementation of a new model face to face and remote pharmaceutical care with home delivery of tyronsine kinase inhibitors medicines for patients with chronic myeloid leukemia. Methods: Patients with chronic myeloid leukemia were selected to start this new model of care....

Full description

Saved in:

Bibliographic Details
Main Authors:	Begoña San José Ruiz, María Angeles Gil Lemus, María Puy Figuero Echeverria
Format:	Article
Language:	English
Published:	Elsevier 2015-01-01
Series:	Farmacia Hospitalaria
Subjects:	Leukemia Myelogenous Chronic BCR-ABL Positive Protein Kinase Inhibitors Patient-Centered Care Telemedicine
Online Access:	http://www.aulamedica.es/fh/pdf/7860.pdf
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Leukemic infiltration of the ovary as an initial presentation of chronic myeloid leukemia in chronic phase
by: Sekulić Borivoj, et al.
Published: (2022-01-01)

Several different cytogenetic clones arising during treatment of Philadelphia positive chronic myeloid leukemia with tyrosine kinase inhibitors lead to the progression into Philadelphia negative acute myeloid leukemia
by: Denčić-Fekete Marija, et al.
Published: (2021-01-01)

Factors associated with achievement and durability of cytogenetic response in patients with chronic myeloid leukemia treated with imatinib
by: Ćojbašić Irena, et al.
Published: (2011-01-01)

Molecular genetics monitoring of tyrosine kinase inhibitor therapy for chronic myeloid leukemia
by: S. I. Kutsev, et al.
Published: (2022-11-01)

Epidemiological characterization of chronic myeloid leukaemia patients at an oncologic centre: A retrospective observational study
by: Ana Maria Meireles, et al.
Published: (2025-07-01)

Efficacy of Bosutinib therapy as a second line in the treatment of chronic myeloid leukemia: A single-center study
by: Alaa Fadhil Alwan, et al.
Published: (2025-01-01)

Chronic myeloid leukemia in childhood: a case report
by: Uma Bhatta, et al.
Published: (2021-09-01)

Dasatinib: ten years of clinical practice worldwide
by: K. M. Abdulkadyrov, et al.
Published: (2016-03-01)

Evaluating the correlation of Age and Gender with the Hematological Parameters of the Chronic Myeloid Leukemia Patients
by: Farooq I. Mohammad, et al.
Published: (2025-04-01)

Evolution of therapeutic approaches in patients with chronic myeloid leukemia and T315I mutation
by: A. G. Turkina, et al.
Published: (2024-12-01)

Mutation status of refractory to imatinib patients with chronic myeloid leukemia
by: E. G. Ovsyannikova, et al.
Published: (2014-07-01)

CLINICAL CASE OF TREATMENT OF A PATIENT WITH CHRONIC MYELOID LEUKEMIA WITH A MUTATION BCR-ABL Y253H AND COMORBIDITIES
by: G. Sh. Safuanova, et al.
Published: (2019-05-01)

Characteristics of BCR::ABL1 kinase domain mutations in Vietnamese chronic myeloid leukemia patients
by: Phu Chi Dung, et al.
Published: (2025-01-01)

From the bench of molecular understanding to the bedside of optimal therapy for BCR::ABL1 and ABL-class acute lymphoblastic leukemia in children and adolescents
by: Sarah K. Tasian, et al.
Published: (2025-12-01)

Tyrosine Kinase Inhibitor Resistance in Patients with Chronic Myeloid Leukemia: A 10-Year Study of BCR-ABL Gene Mutation Profile in Russia (2006–2016)
by: VV Tikhonova, et al.
Published: (2018-07-01)

PF-114, a Novel Inhibitor of Bcr-Abl Chimeric Tyrosine Kinase, Attenuates Intracellular CrkL Phosphorylation and Kills Chronic Myeloid Leukemia Cells
by: ES Kolotova, et al.
Published: (2016-01-01)

BCR-ABL gene amplification in patients with chronic myeloid leukemia and imatinib resistance
by: S. I. Kutzev, et al.
Published: (2022-11-01)

Molecular genetic and cytogenetic determinants of primary resistance or loss of the response to treatment with tyrosine kinase inhibitors in patients with chronic myeloid leukemia.
by: K. Kotlyarchuk, et al.
Published: (2015-09-01)

Design, Docking Analysis, and Structure–Activity Relationship of Ferrocene-Modified Tyrosine Kinase Inhibitors: Insights into BCR-ABL Interactions
by: Irena Philipova, et al.
Published: (2025-07-01)

The Unusual Presentation of Bilateral Proptosis Presents a Dilemma in the Case of Juvenile Myelomonocytic Leukemia
by: Himanshu Gohatre, et al.

BCR::ABL1 expression in chronic myeloid leukemia cells in low oxygen is regulated by glutamine via CD36-mediated fatty acid uptake
by: Caterina Mancini, et al.
Published: (2025-05-01)

The comparative analysis of BCR-ABL/ABL detection by real-time quantitative PCR and automated GeneXpert Dx System in chronic myeloid leukemia patients with major and complete molecular response
by: S. A. Smirnikhina, et al.
Published: (2014-07-01)

Current and future of targeted therapies against BCR::ABL kinases
by: Sridhar Jayavel, et al.
Published: (2025-04-01)

Incidence of BCR-ABL transcript variants in patients with chronic myeloid leukemia: Their correlation with presenting features, risk scores and response to treatment with imatinib mesylate
by: Pratik Deb, et al.
Published: (2014-01-01)

HSP90 inhibitors promote cell death by degrading Met and BCR::ABL1 in both imatinib-resistant and -sensitive chronic myeloid leukemia cells
by: Masanobu Tsubaki, et al.
Published: (2025-01-01)

Novel e4a2 BCR∷ABL1 transcript with insertion of CSE1L exons 9 and 10 in a CML patient: a case report
by: Sara Di Giusto, et al.
Published: (2025-08-01)

A review of immunotargeted therapy for Philadelphia chromosome positive acute lymphoblastic leukaemia: making progress in chemotherapy-free regimens
by: Zhen-Yu Xiong, et al.
Published: (2024-12-01)

Chronic Myelogenous Leukemia Patients on Tyrosine Kinase Inhibitors—Hematological Changes and Correlation with European Leukemia Network Response Criteria
by: Karthik Bommannan, et al.

A network-based approach to overcome BCR::ABL1-independent resistance in chronic myeloid leukemia
by: Valeria Bica, et al.
Published: (2025-04-01)

Philadelphia chromosome-positive mixed-phenotype acute leukemia: a case report and literature review
by: Liqing Yang, et al.
Published: (2025-07-01)

A decade-long analysis of 98 chronic myeloid leukemia patients: Laboratory data and clinical progress at a single center
by: Nabihah Mohd Shakri, et al.
Published: (2025-01-01)

DOWNREGULATION OF STEAROYL-COA DESATURASE 1 (SCD-1) PROMOTES RESISTANCE TO IMATINIB IN CHRONIC MYELOID LEUKEMIA
by: Buket Altinok Gunes, et al.
Published: (2023-01-01)

Pharmacoeconomic modeling of target therapy of chronic myeloid leukemia in remission
by: V. A. Shuvaev, et al.
Published: (2015-01-01)

The biology of chronic myeloid leukemia: an overview of the new insights and biomarkers
by: Anna Sicuranza, et al.
Published: (2025-05-01)

Fungal secondary metabolites as a potential inhibitor of T315I- BCR::ABL1 mutant in chronic myeloid leukemia by molecular docking, molecular dynamics simulation and binding free energy exploration approaches
by: Dilinazi Abulaiti, et al.
Published: (2024-12-01)

Computational Insights into the Polypharmacological Landscape of BCR-ABL Inhibitors: Emphasis on Imatinib and Nilotinib
by: Rima Hajjo, et al.
Published: (2025-06-01)

Acute myelogenous leukemia revealed by acute appendicitis
by: Sanae El Marzguioui, et al.
Published: (2020-01-01)

Glivec: A New Treatment Modality for CML: A Case History
by: Jürg Zimmermann
Published: (2002-08-01)

Single-cell multiomics analysis of chronic myeloid leukemia links cellular heterogeneity to therapy response
by: Rebecca Warfvinge, et al.
Published: (2024-11-01)

Corrigendum: Dogs with acute myeloid leukemia have clonal rearrangements in T and B cell receptors
by: Tracy Stokol, et al.
Published: (2025-01-01)